DeepMed Research

Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

Phase 4

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Calcium/Vit D
Drug: Bazedoxifene

First Posted Date: 2014-03-18

Last Posted Date: 2015-09-09

Lead Sponsor: Instituto Palacios

Target Recruit Count: 110

Registration Number: NCT02090400

Locations: 🇪🇸
Gabinete Médico Velázquez, Madrid, Spain
🇪🇸
Instituto Palacios, Madrid, Spain
🇪🇸
Instituto de Ginecología EGR, Madrid, Spain

Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination

Not Applicable

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: oral vitamin D
Drug: Placebo

First Posted Date: 2014-02-07

Last Posted Date: 2014-02-07

Lead Sponsor: Srinakharinwirot University

Target Recruit Count: 20

Registration Number: NCT02058186

Locations: 🇹🇭
Skin Center, Srinakharinwirot University, Bangkok, Thailand

Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial

Phase 2

Completed

Conditions: HIV

Interventions: Drug: alendronate/vitamin D

First Posted Date: 2013-10-24

Last Posted Date: 2018-04-19

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 30

Registration Number: NCT01968850

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment D
Drug: Treatment C
Drug: Treatment E

First Posted Date: 2013-07-12

Last Posted Date: 2014-12-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT01897389

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Treatment A
Drug: Treatment D
Drug: Treatment B
Drug: Treatment C
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H
Drug: Treatment I
Drug: Treatment J

First Posted Date: 2013-04-26

Last Posted Date: 2014-02-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 56

Registration Number: NCT01841489

Locations: 🇺🇸
Investigational Site, Daytona Beach, Florida, United States

Vitamin D Treatment and Hypogonadism in Men

Phase 4

Completed

Conditions: Hypogonadism

Interventions: Drug: Vitamin D supplementation in hypogonadal men
Drug: Vitamin D supplementation in eugonadal men
Drug: Placebo eugonadal
Drug: Placebo hypogonadal

First Posted Date: 2012-12-12

Last Posted Date: 2018-03-20

Lead Sponsor: Medical University of Graz

Target Recruit Count: 200

Registration Number: NCT01748370

Locations: 🇦🇹
Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism, Graz, Austria

Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2

Phase 4

Completed

Conditions: Vitamin D Deficiency
Diabetes Mellitus Type 2

Interventions: Drug: Vitamin D supplementation
Drug: Placebo Pill

First Posted Date: 2012-12-04

Last Posted Date: 2014-11-18

Lead Sponsor: Tan Tock Seng Hospital

Target Recruit Count: 64

Registration Number: NCT01741181

Locations: 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore

Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism

Phase 4

Completed

Conditions: Healthy
Polycystic Ovary Syndrome
Vitamin D Deficiency

Interventions: Drug: Placebo
Drug: Vitamin D supplementation

First Posted Date: 2012-11-06

Last Posted Date: 2018-03-20

Lead Sponsor: Medical University of Graz

Target Recruit Count: 330

Registration Number: NCT01721915

Locations: 🇦🇹
Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism, Graz, Austria

Immune Reconstitution in HIV Disease (IREHIV)

Phase 2

Completed

Conditions: HIV Infection

Interventions: Drug: Placebo tablets
Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)

First Posted Date: 2012-10-10

Last Posted Date: 2016-02-05

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 279

Registration Number: NCT01702974

Locations: 🇪🇹
Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine, Addis Ababa, Lideta sub city, Ethiopia

Immune Reconstitution in Tuberculosis Disease

Phase 2

Completed

Conditions: Pulmonary Tuberculosis (TB)

Interventions: Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
Drug: Placebo tablets

First Posted Date: 2012-10-03

Last Posted Date: 2016-02-05

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 390

Registration Number: NCT01698476

Locations: 🇪🇹
Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine, Addis Ababa, Lideta sub city, Ethiopia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy